IRIDEX (NASDAQ:IRIX – Get Free Report) released its earnings results on Tuesday. The medical equipment provider reported ($0.12) earnings per share for the quarter, Zacks reports. IRIDEX had a negative return on equity of 163.45% and a negative net margin of 22.79%. The business had revenue of $11.58 million during the quarter. During the same quarter last year, the firm posted ($0.11) EPS.
IRIDEX Stock Performance
IRIX stock traded down $0.04 during trading on Thursday, reaching $1.85. 52,431 shares of the company traded hands, compared to its average volume of 31,245. The company has a market capitalization of $30.54 million, a price-to-earnings ratio of -2.82 and a beta of 0.80. The business has a 50 day simple moving average of $1.68 and a 200 day simple moving average of $2.03. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on shares of IRIDEX in a report on Saturday, November 9th. They issued a “hold” rating for the company.
About IRIDEX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Featured Articles
- Five stocks we like better than IRIDEX
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- How to Calculate Return on Investment (ROI)
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What are earnings reports?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.